Weight Watchers Beats 2025 Guidance as GLP-1 Clinical Subscribers Jump 42%
WW International reported Q4 and full-year 2025 results beating guidance, with strong growth in clinical subscribers thanks to GLP-1 integration.
/ 7 items
#WW↓
Texas Pharmacy Sues Eli Lilly and Novo Nordisk Over GLP-1 Weight-Loss Drug Access
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
Amazon Pharmacy Now Offers Wegovy Weight-Loss Pill with Affordable Options
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Weight Watchers Launches All-in-One Weight Management Platform
Weight Watchers unveils integrated platform combining GLP-1 medications, personalized nutrition, AI tracking, and community support for sustainable weight loss results.